Stratification of patients with epithelial ovarian carcinoma into high- and low-risk categories

CME Journal of Gynecologic Oncology

Volumn 5, Issue 3, 2000, Pages 231-234

  Geisler, J P ^a   Geisler, H E ^a   Miller, G A ^a   Tammela, J ^a   Wiemann, M C ^a   Zhou, Z ^a   Crabtree, W ^a  

^a St Vincent Hospitals and Health Services   (United States)

Author keywords

High risk; Low risk; Ovarian cancer; Prognostic factors

Indexed keywords

DNA; MONOCLONAL ANTIBODY KI 67;

CANCER CELL; CANCER GENETICS; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CYTOPATHOLOGY; EPITHELIUM TUMOR; GYNECOLOGY; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; MEDICAL SPECIALIST; ONCOLOGY; OVARY CARCINOMA; PATIENT CODING; PROGNOSIS; RESIDENCY EDUCATION; REVIEW;

EID: 0034521946     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Cancer Statistics, 1999
2. The adnexal mass and early ovarian cancer
3. Epithelial ovarian cancer
4. The surgeon as a prognostic factor
5. Misstaging of ovarian cancer
6. Patterns of care in carcinoma of the ovary
7. Staging laparotomy in early ovarian cancer
8. Ovarian cancer staging: Does it require a gynecologic oncologist?
9. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
10. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study
11. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer
12. The impact of subspecialty training on the management of advanced ovarian cancer
13. Optimal cytoreductive surgery in the elderly woman with stage IIIc serous cystadenocarcinoma of the ovary
14. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer
15. The prognostic variability of ovarian tumor grading by different pathologists
16. Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up
17. Quantitative prognostic features in F1-GO I ovarian cancer patients without postoperative treatment
18. Nuclear shape: An independent predictor of survival in patients with ovarian carcinoma
19. Markov Optical Texture Parameters as Prognostic Indicators in Ovarian Carcinoma
20. Quantitative pathological prognostic factors in epithelial ovarian cancer
21. Clinical significance of abnormal nuclear DNA content in serous ovarian tumors
22. Flow cytometric analysis of nuclear DNA ploidy in ovarian tumors. Association of ploidy with tumour type, histologic grade, and clinical stage
23. DNA ploidy in epithelial ovarian cancer: A new prognostic factor!
24. DNA index reflects the biological behavior of ovarian carcinoma stage I-IIa
25. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer
26. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis
27. Ki67 immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: Index of proliferative activity with prognostic significance
28. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis
29. The combined evaluation of p53 accumulation and Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients
30. Oncogene expression: Long-term compared with short-term survival in patients with advanced epithelial ovarian cancer
31. Clinical significance of a-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer
32. MIB-1: A predictor of survival in patients with ovarian carcinoma
33. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease
34. Clear cell carcinoma of the ovary: Poor prognosis compared to serous carcinoma
35. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer
36. Five year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma
37. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression free survival in stage III and IV ovarian carcinoma